← Back to Clinical Trials
Recruiting Phase 3 NCT07186413

NCT07186413 A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07186413
Status Recruiting
Phase Phase 3
Sponsor Galderma R&D
Condition Acne Vulgaris
Study Type INTERVENTIONAL
Enrollment 561 participants
Start Date 2025-09-23
Primary Completion 2026-12-31

Trial Parameters

Condition Acne Vulgaris
Sponsor Galderma R&D
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 561
Sex ALL
Min Age 9 Years
Max Age N/A
Start Date 2025-09-23
Completion 2026-12-31
Interventions
TrifaroteneVehicle Cream

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.

Eligibility Criteria

Inclusion Criteria: Participants must meet the following criteria to be included in the study: 1. Male or female Chinese participants aged 9 years or older at the screening visit. 2. A minimum of 20 inflammatory lesions and 25 non-inflammatory lesions on the face at Screening and Baseline. 3. Facial acne vulgaris severity grade 3 (moderate) on the IGA scale at Screening and Baseline. 4. A minimum of 20 inflammatory lesions and 20 non-inflammatory lesions but no more than 100 non-inflammatory lesion counts on the trunk (shoulders, upper back, and upper anterior chest) reachable for self-application of investigational product by the participant at Screening and Baseline (optional criterion for participant between 9 and 11 years of age). 5. Acne vulgaris severity grade 3 (moderate) on the PGA scale at Screening and Baseline visits on trunk (shoulders, upper back and upper anterior chest) reachable for self-application of investigational product by the participant (optional criterion for p

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology